Zai Lab

ZLAB · Nasdaq · China

Share price · ZLAB

$22.11-3.46 (-13.53%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.0M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ZLAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+12.7%
  2. 23 Oct 2026+9.0%
  3. 22 Oct 2026-8.9%
  4. 11 Aug 2026+10.3%
  5. 7 Aug 2026+11.7%
  6. 6 Aug 2026+13.7%
  7. 18 May 2026-8.4%
  8. 22 Apr 2026-6.4%
  9. 1 Apr 2026+8.1%
  10. 4 Mar 2026+8.7%

Share of unusual movement by asset

For each asset, the share of ZLAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tisotumab Vedotin Humax-tf-adc (Tivdak)
events and moves
7shown from 8 days
ZL-1503
events and moves
6shown from 8 days
Repotrectinib
events and moves
6shown from 8 days
Xanomeline/trospium chloride (Cobenfy)
events and moves
6shown from 8 days
Efgartigimod Alfa (Vyvgart)
events and moves
2shown from 8 days
Niraparib
events and moves
1shown from 8 days
Adagrasib (Krazati)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—14%
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—69%

Assets

(7 total)
7Total Assets
6Approved
0Phase 3 / Filed
1Phase 1–2 / Early
11Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Adagrasib(Krazati)
Approved
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Approved
FcRnAntibody fragment
Myasthenia GravisChronic Inflammatory Demyelinating Polyneuropathy
Generalized Myasthenia Gravis
Approved
PARP1/2Small molecule
Non-Small Cell Lung CancerOvarian CancerGlioblastoma
Approved
ROS1/NTRKSmall molecule
Non-Small Cell Lung CancerSolid Tumors
ROS1-Positive Non-Small Cell Lung Cancer
Approved
Tissue Factor (TF)Antibody–drug conjugate
Non-Small Cell Lung CancerCervical Cancer
Approved
Muscarinic M1/M4 receptor (agonist/antagonist combination)Small molecule
Alzheimer's DiseaseSchizophreniaBipolar Disorder
Phase 1
IL-13 and IL-31 receptor A (IL-31RA)Multispecific antibody
Atopic Dermatitis

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(21 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
Est. primary completion 2026-11-24 · NCT06585787 · CT.gov ↗
What to watch
NiraparibPhase 3Neoplasms
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
December 2026 (2)
Xanomeline/trospium chloride · CobenfyPhase 3Psychosis Associated With Alzheimer's Disease
Est. primary completion 2026-12-09 · NCT06126224 · CT.gov ↗
What to watch
NiraparibPhase 2Ovarian Neoplasms, Breast Neoplasms
Est. primary completion 2026-12-28 · NCT04641247 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
RepotrectinibPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-02-16 · NCT06140836 · CT.gov ↗
What to watch
June 2027 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Mania, Bipolar Disorder
Est. primary completion 2027-06-28 · NCT07140913 · CT.gov ↗
What to watch
September 2027 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Psychosis Associated With Alzheimer's Disease
Est. primary completion 2027-09-07 · NCT05980949 · CT.gov ↗
What to watch
2028 (8)
February 2028 (2)
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer Disease, Psychosis
Est. primary completion 2028-02-21 · NCT06947941 · CT.gov ↗
What to watch
RepotrectinibPhase 1/2Locally Advanced Solid Tumors, Metastatic Solid Tumors
Est. primary completion 2028-02-29 · NCT03093116 · CT.gov ↗
What to watch
June 2028 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Bipolar Disorder Type I With Mania
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch
September 2028 (3)
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-09-11 · NCT06976203 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-09-11 · NCT06976216 · CT.gov ↗
What to watch
Est. primary completion 2028-09-23 · NCT06882785 · CT.gov ↗
What to watch
November 2028 (2)
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-11-03 · NCT07011745 · CT.gov ↗
What to watch
Est. primary completion 2028-11-24 · NCT07011732 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Est. primary completion 2029-03-03 · NCT07686263 · CT.gov ↗
What to watch
June 2029 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer Disease, Agitation
Est. primary completion 2029-06-22 · NCT06937229 · CT.gov ↗
What to watch
August 2029 (2)
Xanomeline/trospium chloride · CobenfyPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2029-08-06 · NCT07284745 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2029-08-06 · NCT07285798 · CT.gov ↗
What to watch
December 2029 (1)
Est. primary completion 2029-12-18 · NCT07288567 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Schizophrenia, Autism-Related Irritability
Est. primary completion 2030-03-08 · NCT07424404 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 September 2026WithdrawalAdagrasib (Krazati)FDA approves voluntary withdrawal of the Krazati colorectal cancer indication after KRYSTAL-10 (NCT04793958)
US, FDA · Bristol-Myers Squibb Company · Source ↗
8 June 2026ApprovalTisotumab Vedotin Humax-tf-adcNMPA approves TIVDAK for recurrent or metastatic cervical cancer
CN, NMPA · Source ↗
9 March 2026ApprovalNiraparibEC approves AKEEGA indication extension for BRCA1/2-mutated mHSPC
EU, EC · Source ↗
6 January 2026ApprovalRepotrectinibNMPA approves AUGTYRO for NTRK-positive solid tumors
CN, NMPA · Source ↗
23 December 2025ApprovalXanomeline/trospium chlorideNMPA approves COBENFY for schizophrenia in China
CN, NMPA · Source ↗
1 September 2025ApprovalTisotumab Vedotin Humax-tf-adcTIVDAK approved in Hong Kong
HK, Hong Kong Department of Health · Source ↗
21 April 2025Filing acceptedRepotrectinibNMPA accepts sNDA for repotrectinib in NTRK-positive solid tumors
CN, NMPA · Source ↗
February 2025Priority reviewRepotrectinibNMPA grants priority review to repotrectinib for NTRK-positive solid tumors
CN, NMPA · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$108M$50M$550M+ $10M short-term inv.$46M-$58M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$106M$62M$608M+ $10M short-term inv.$51M-$63M operating cash flowreport ↗
2026-Q1$100M$66M$761M$51Mreport ↗
2025-Q3$115M$48M$717M+ $0 short-term inv.$36M-$32M operating cash flowreport ↗
2025-Q2$109M$51M$732M+ $0 short-term inv.$41M-$31M operating cash flowreport ↗
2025-Q1$106M$61M$757M+ $0 short-term inv.$48M-$62M operating cash flowreport ↗
2024-Q3$102M$66M$616M+ $0 short-term inv.$42M-$27M operating cash flowreport ↗
2024-Q2$100M$62M$630M+ $0 short-term inv.$80M-$42M operating cash flowreport ↗
2024-Q1$87M$55M$651M+ $0 short-term inv.$53M-$90M operating cash flowreport ↗
2023-Q3$69M$59M$789M+ $32M short-term inv.$69M-$55M operating cash flowreport ↗
2023-Q2$69M$77M$859M+ $16M short-term inv.$121M-$59M operating cash flowreport ↗
2023-Q1$63M$48M$880M+ $51M short-term inv.$49M-$69M operating cash flowreport ↗
2022-Q3$57M$100M$1.1B+ $0 short-term inv.$161M-$126M operating cash flowreport ↗
2022-Q2$48M$66M$681M+ $575M short-term inv.$138M-$45M operating cash flowreport ↗
2022-Q1$46M$54M$847M+ $465M short-term inv.$82M-$87M operating cash flowreport ↗
2021-Q4$44M—$964M+ $445M short-term inv.$212M-$153M operating cash flowreport ↗
2021-Q3$43M$55M$1.4B+ $170M short-term inv.$96M-$161M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$457M$221M$680M+ $10M short-term inv.$44M-$151M operating cash flowreport ↗

Zai Lab reported full-year 2025 product revenue of $457.18M, up 15.0% YoY from $397.61M, with R&D spend of $220.9M, down 5.8% YoY from $234.5M. Cash and equivalents stood at $679.57M, and the company recorded a net loss of $175.54M.

The company highlighted that zocilurtatug pelitecan is on track to be its first global oncology launch, with three registration-enabling studies planned across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026. It is also advancing ZL-1503, ZL-6201, ZL-1222, and ZL-1311, while KarXT was approved in China with commercial launch preparations underway. Pivotal readouts for povetacicept in IgAN and elegrobart in TED are expected in 2026, and the FDA approved Optune Pax for locally advanced pancreatic cancer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$398M$235M$450M+ $330M short-term inv.$64M-$215M operating cash flowreport ↗
2023-FY$267M$266M$790M+ $16M short-term inv.$84M-$198M operating cash flowreport ↗
2022-FY$213M$286M$1.0B+ $0 short-term inv.$111M-$368M operating cash flowreport ↗
2021-FY$144M$573M$964M+ $445M short-term inv.$176M-$549M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($99K), 39 sales ($11.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10GAYNOR RICHARD · directorOpen-market purchase1,228$27.19$33KForm 4
2026-10-01Chen Yajing · Chief Financial OfficerOption exercise920——Form 4
2026-10-01Chen Yajing · Chief Financial OfficerTax withholding315$25.50$8KForm 4
2026-10-01Chen Yajing · Chief Financial OfficerOption exercise (derivative)920——Form 4
2026-08-19Chen Yajing · Chief Financial OfficerOpen-market sale260$27.00$7KForm 4
2026-08-14Chen Yajing · Chief Financial OfficerOption exercise1,250——Form 4
2026-08-14Chen Yajing · Chief Financial OfficerTax withholding427$25.90$11KForm 4
2026-08-14Chen Yajing · Chief Financial OfficerOption exercise (derivative)1,250——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 28.2M shares ($515.7M).

#InstitutionSharesValue
1RTW INVESTMENTS, LP6,574,032$123.7M
2RA CAPITAL MANAGEMENT, L.P.5,707,262$107.4M
3Frazier Life Sciences Management, L.P.1,902,320$35.8M
4CITADEL ADVISORS LLC1,688,632$31.8M
5BAMCO INC /NY/1,658,318$31.2M
6ADAR1 Capital Management, LLC1,425,367$26.8M
7FMR LLC1,262,391$23.7M
8BlackRock, Inc.865,146$16.3M
9Rock Springs Capital Management LP814,707$15.3M
10UBS Group AG504,191$9.5M
11B Group, Inc.450,646$8.5M
12SCHRODER INVESTMENT MANAGEMENT GROUP393,167$7.0M
13NAN FUNG TRINITY (HK) LTD346,466$6.5M
14TWO SIGMA INVESTMENTS, LP309,723$5.8M
15SUPERSTRING CAPITAL MANAGEMENT LP275,818$5.2M